Eisai to Present New Research on Halaven (Eribulin) at 36th Annual San Antonio
Breast Cancer Symposium
Tokyo, Dec 5, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo,
President & CEO: Haruo Naito, "Eisai") announced today that new
clinical study results on the company's novel anticancer agent Halaven
(eribulin mesylate) will be presented during the 2013 San Antonio Breast Cancer
Symposium (SABCS). The symposium will be held from December 10 through 14,
2013, in San Antonio, Texas in the United States.
The studies reflect Eisai's current and ongoing research efforts to
establish the clinical benefits of Halaven and maximize the drug's value.
The studies to be presented at this year's SABCS highlight the
company's current oncology product portfolio strategy and research
accomplishments in this field.
Eisai positions oncology as a key franchise area. The company will continue to
create innovation in the development of new drugs based on cutting-edge cancer
research in order to make further contributions to address the diversified
needs of, and increase the benefits provided to, patients and their families as
well as healthcare providers.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net
Provider ID: 00028144
Press spacebar to pause and continue. Press esc to stop.